SEC Company Response from Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746) (ACRS) — Apr 23, 2020
Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746)
Date: April 23, 2020 · CIK: 0001557746 · Accession: 0001104659-20-050082
AI Filing Summary & Sentiment
File numbers found in text: 333-237163
Letter
Re: Aclaris Therapeutics, Inc. (the “Company”)
April 23, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Will Mastrianna
Registration Statement on Form S-3
Filed: March 13, 2020
File No. 333-237163
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m. Eastern Time on April 27, 2020 or as soon thereafter as is practicable, or at such later time as the Company may orally request via telephone call to the staff. The Company hereby authorizes each of Brian Leaf, Mark Ballantyne and Rasha Azouqha of Cooley LLP to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053, or in his absence, Mark Ballantyne of Cooley LLP at (703) 456-8084.
Very truly yours,
Aclaris Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm April 23, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Will Mastrianna Re: Aclaris Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: March 13, 2020 File No. 333-237163 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m. Eastern Time on April 27, 2020 or as soon thereafter as is practicable, or at such later time as the Company may orally request via telephone call to the staff. The Company hereby authorizes each of Brian Leaf, Mark Ballantyne and Rasha Azouqha of Cooley LLP to make such request on its behalf. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053, or in his absence, Mark Ballantyne of Cooley LLP at (703) 456-8084. Very truly yours, Aclaris Therapeutics, Inc. By: /s/ Frank Ruffo Frank Ruffo Chief Financial Officer